Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 24754564)

1.

Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone.

Beermann KJ, Ellis MJ, Sudan DL, Harris MT.

Clin Transplant. 2014 Jul;28(7):762-7. doi: 10.1111/ctr.12376. Epub 2014 May 23.

PMID:
24754564
2.

Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.

Narayanan M, Pankewycz O, El-Ghoroury M, Shihab F, Wiland A, McCague K, Chan L.

Transplantation. 2013 Feb 27;95(4):566-72. doi: 10.1097/TP.0b013e318277438f.

PMID:
23423268
3.

Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study.

Narayanan M, Pankewycz O, Shihab F, Wiland A, McCague K, Chan L.

Clin Transplant. 2014 Feb;28(2):184-91. doi: 10.1111/ctr.12294. Epub 2013 Dec 24.

PMID:
24372743
4.

Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.

Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.

Clin Transplant. 2013 Jul-Aug;27(4):E359-67. doi: 10.1111/ctr.12141. Epub 2013 May 26.

PMID:
23710603
5.

Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.

Shihab FS, Olyaei A, Wiland A, McCague K, Norman DJ.

Clin Transplant. 2014 Jul;28(7):768-75. doi: 10.1111/ctr.12377. Epub 2014 May 21.

PMID:
24754603
6.

Effect of mycophenolate mofetil on long-term outcomes in African american renal transplant recipients.

Meier-Kriesche HU, Ojo AO, Leichtman AB, Punch JD, Hanson JA, Cibrik DM, Kaplan B.

J Am Soc Nephrol. 2000 Dec;11(12):2366-70.

7.

African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help?

Laftavi MR, Pankewycz O, Patel S, Nader N, Kohli R, Feng L, Said M, Dayton M.

Transplant Proc. 2013;45(10):3498-501. doi: 10.1016/j.transproceed.2013.09.010.

PMID:
24314941
8.
10.
11.
12.

Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?

Li P, Shuker N, Hesselink DA, van Schaik RH, Zhang X, van Gelder T.

Transpl Int. 2014 Oct;27(10):994-1004. doi: 10.1111/tri.12382. Epub 2014 Aug 22. Review.

PMID:
24963914
13.

Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.

Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.

Clin J Am Soc Nephrol. 2012 Mar;7(3):504-12. doi: 10.2215/CJN.06940711. Epub 2012 Jan 26.

14.

Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.

Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.

Transpl Infect Dis. 2001 Mar;3(1):8-15.

PMID:
11429034
15.

Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients: a case-control study.

Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO.

Clin Transplant. 2000 Dec;14(6):572-9.

PMID:
11127311
16.

Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy.

Weber M, Deng S, Arenas J, Aradhye S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL.

Transplant Proc. 1997 Dec;29(8):3669-70. No abstract available.

PMID:
9414883
17.

Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients.

Taber DJ, Belk L, Meadows H, Pilch N, Fleming J, Srinivas T, McGillicuddy J, Bratton C, Chavin K, Baliga P.

Ther Drug Monit. 2013 Dec;35(6):753-9. doi: 10.1097/FTD.0b013e31829a7a7c.

19.

Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.

Budde K, Bunnapradist S, Grinyo JM, Ciechanowski K, Denny JE, Silva HT, Rostaing L; Envarsus study group.

Am J Transplant. 2014 Dec;14(12):2796-806. doi: 10.1111/ajt.12955. Epub 2014 Oct 2.

20.

Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.

Ahsan N, Johnson C, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Salm K, Tolzman D, Fitzsimmons WE.

Transplantation. 2001 Jul 27;72(2):245-50.

PMID:
11477347
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk